John Nuss

Company: Ventyx Biosciences

Job title: CSO

Seminars:

Detailing the Promising Clinical Outcomes from Phase 2 Trial of VTX2735 in Cryopyrin-Associated Periodic Syndromes (CAPS) 8:00 am

Exploring the clinical validation of VTX2735 in CAPS with topline phase 2 data showing an 85% mean reduction in Key Symptom Score, affirming VTX2735’s potential as a peripheral NLRP3 inhibitor for CAPS treatment Exploring VTX2735’s potential in cardiovascular diseases, with a focus on MACE prevention and recurrent pericarditis an opportunity to address unmet medical needsRead more

day: Day 1